Murakami S, Yamagishi I, Asami Y, Sato M, Tomisawa K
Medicinal Research Laboratories, Taisho Pharmaceutical Co., Saitama, Japan.
Cell Mol Biol (Noisy-le-grand). 1996 Sep;42(6):865-72.
The effects of a novel acyl-CoA: cholesterol acyltransferase (ACAT) inhibitor, HL-004, on cholesterol metabolism were examined in mice peritoneal macrophages. Cholesteryl ester-rich foam cells were induced by incubating macrophages with acetylated LDL. HL-004 prevented the accumulation of cholesteryl ester in the presence of the cholesterol acceptor, HDL. In the absence of HDL, HL-004 generated large amounts of free cholesterol in the cell. Moreover, HL-004 stimulated the efflux of cholesterol from preestablished foam cells in the presence of HDL. These results suggest that the inhibition of foam cell formation and the stimulation of foam cell regression by HL-004 are attributed to intracellular ACAT inhibition, and that HL-004 would be expected to exhibit an antiatherosclerotic effect through direct action on arterial wall.
在小鼠腹腔巨噬细胞中检测了新型酰基辅酶A:胆固醇酰基转移酶(ACAT)抑制剂HL-004对胆固醇代谢的影响。通过用乙酰化低密度脂蛋白孵育巨噬细胞诱导富含胆固醇酯的泡沫细胞。在存在胆固醇受体高密度脂蛋白(HDL)的情况下,HL-004可防止胆固醇酯的积累。在没有HDL的情况下,HL-004在细胞中产生大量游离胆固醇。此外,在存在HDL的情况下,HL-004刺激预先形成的泡沫细胞中的胆固醇流出。这些结果表明,HL-004对泡沫细胞形成的抑制和对泡沫细胞消退的刺激归因于细胞内ACAT的抑制,并且预期HL-004通过对动脉壁的直接作用表现出抗动脉粥样硬化作用。